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Objective:Ghrelin, a stomach-derived, secreted peptide, and its receptor (growth hormone
secretagogue receptor, GHSR) are known to modulate food intake and energy homeosta-
sis. The ghrelin system is also expressed broadly in cardiovascular tissues. Since ghrelin
has been associated with anti-inflammatory and anti-atherogenic properties, but is also
well known to promote obesity and impair glucose metabolism, we investigated whether
ghrelin has any impact on the development of atherosclerosis.The hypothesis that endoge-
nous ghrelin signaling may be involved in atherosclerosis has not been tested previously.
Methods and Results:We crossed ghrelin receptor knockout mice (GHSr−/−) into a low-
density lipoprotein receptor-null (Ldlr−/−) mouse line. In this model, atherosclerotic lesions
were promoted by feeding a high-fat, high-cholesterol Western-type diet for 13months,
following a standard protocol. Body composition and glucose homeostasis were similar
between Ldlr−/− and Ldlr/GHSR−/−ko mice throughout the study. Absence or presence
of GHSr did not alter the apolipoprotein profile changes in response to diet exposure
on an LDLRko background. Atherosclerotic plaque volume in the aortic arch and thoracic
aorta were also not affected differentially in mice without ghrelin signaling due to GHSR
gene disruption as compared to control LDLRko littermates. In light of the associations
reported for ghrelin with cardiovascular disease in humans, the lack of a phenotype in
these loss-of-function studies in mice suggests no direct role for endogenous ghrelin in
either the inhibition or the promotion of diet-induced atherosclerosis. Conclusion: These
data indicate that, surprisingly, the complex and multifaceted actions of endogenous ghre-
lin receptor mediated signaling on the cardiovascular system have minimal direct impact
on atherosclerotic plaque progression as based on a loss-of-function mouse model of the
disease.
Keywords: ghrelin, LDL receptor, atherosclerosis
INTRODUCTION
As obesity rates continue to rise in the United States, the risk for
mortality from its comorbidities is also accelerating. Among the
most concerning of these associated disease states are cardiovascu-
lar events, which besides being correlated with obesity (Jousilahti
et al., 1996; McGill et al., 2002), are also associated with many
other obesity-derived comorbidities such as hypertension, dys-
lipidemia, hyperinsulinemia, and diabetes mellitus (McGill et al.,
1997, 1998; Calle et al., 1999; Fontaine et al., 2003; Banerjee et al.,
2011). This increase in obesity-related atherosclerosis has spurred
intense research into shared pathways that may be essential to
mediating both pathologies. Among the mutual regulators, recent
associations have implicated ghrelin as a protective agent against
atherosclerosis (Zhang et al., 2010).
The 28-amino acid peptide ghrelin is produced in the stomach
and has been identified as the endogenous ligand for the growth
hormone secretagogue receptor (GHSr; (Kojima et al., 1999). It
circulates in two distinct forms, acylated ghrelin and unacylated
ghrelin; its acylated form is essential for binding to the GHSr and
for its primary endocrine functions, including stimulation of GH
secretion from the hypophysis, induction of food intake and reg-
ulation of energy homeostasis (Gutierrez et al., 2008). Recently,
ghrelin and its receptors have been detected in cardiovascular
tissues (Matsubara et al., 1995; Christodoulou et al., 2006) indi-
cating that the peptide may play a role in cardiovascular disease.
Indeed, ghrelin has been shown to inhibit cardiomyocyte and
endothelial cell inflammation and apoptosis (Iglesias et al., 2004;
Li et al., 2004). Furthermore, ghrelin enhances left ventricular
function during ischemia–reperfusion injury in rodents (Chang
et al., 2004), improves left ventricular dysfunction and attenu-
ates the development of cardiac cachexia in rats (Xu et al., 2005).
Ghrelin has also been suggested to reduce mortality and correct
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the hemodynamic and metabolic abnormalities associated with
endotoxic shock in rats (Chang et al., 2003). Similarly, in humans,
ghrelin exerts vasodilatory effects, improves cardiac function and
decreases systemic vascular resistance in chronic heart failure (for
review see Granata et al., 2011).
Thus, ghrelin has been repeatedly inferred to modulate the
atherogenetic process, although the reports in this area are not
all aligned: Ghrelin may play an anti-atherosclerotic role by
inhibiting proinflammatory cytokine production, mononuclear
cell binding, and nuclear factor-kappaB activation in human
endothelial cells in vitro and endotoxin-induced cytokine produc-
tion in rats (Li et al., 2004). In addition, ghrelin may improve
endothelial function and decrease apoptosis by enhancing NO
production (Suematsu et al., 2005; Zhao et al., 2007). Circu-
lating ghrelin concentrations are reportedly increased in men
with atherosclerosis (Poykko et al., 2006) and analyses of ather-
osclerotic lesions in rats and humans have detected expression
of elevated levels of the ghrelin receptor, underscoring a poten-
tial role of the novel vasodilator ghrelin in the pathogenesis of
cardiovascular disease. To further complicate the picture, circu-
lating ghrelin concentrations are reduced in obese patients rais-
ing the possibility that a reduction in endogenous ghrelin could
potentially contribute to inflammatory states and increased inci-
dence of atherosclerosis in obese patients. However, none of these
studies allowed for conclusions on the functions of endogenous
ghrelin as no in vivo loss-of-function models were used and
applied to an appropriate and well-established mouse model of
atherosclerosis.
In the present investigation, we therefore generated such a
unique model and analyzed ghrelin receptor-dependent effects on
the progression of atherosclerosis in mice. We examined lesion
size in ghrelin receptor (GSHr−/−) and low-density lipoprotein
receptor (LDLr−/−) –deficientmousemodels. In our experimental
paradigm, ablation of the ghrelin receptor did not reveal beneficial
effects on the course of cardiovascular disease.
MATERIALS AND METHODS
ANIMALS AND DIET
Growth hormone secretagogue receptor-(Wortley et al., 2004) and
LDLr-deficient mice were obtained from Regeneron Pharmaceu-
ticals (Abizaid et al., 2006; Tarrytown, NY, USA) and the Jackson
Laboratory (Bar Harbor, ME, USA), respectively. Mice from both
lines were bred in our facilities and maintained on a C57/B6 back-
ground. LDLr knockout (LDLr−/−) mice of both sexes were inter-
crossed with GHSr−/− mice to generate a double-heterozygous
generation. Double-heterozygous mice were inbred to produce
mice deficient for both LDLr and GHSr (LDLr/GSHr−/−), or for
LDLr only (LDLr−/−). DNAwas extracted from tail snips and PCR
used to establish genotypes. All animals were housed on a 12:12-h
light–dark cycle at 22˚C. At 12 weeks old, mice were placed on a
Western-style diet obtained from Teklad Custom Research Diets
(TD.88137, Harlan Laboratories, Inc, Indianapolis, IN, USA) with
free access to food and water. All studies were conducted in male,
age-matched mice provided with western diet for 13 months. All
studies were approved by, and performed according to, the guide-
lines of the Institutional Animal Care and Use Committee of the
University of Cincinnati.
BODY COMPOSITION ANALYSIS AND GLUCOSE TOLERANCE TEST
Whole body composition (fat and lean mass) was measured using
NMR technology (EchoMRI, Houston, TX, USA). For measure-
ments of glucose tolerance, mice were fasted for 6 h and injected
intraperitoneally with 50% d-glucose (Sigma) in 0.9% saline, such
that the final dose was 1.5 g glucose/kg body wt in all animals.
Glucose levels (mg/dl) were measured from tail blood using a
handheld glucometer (Freestyle lite) before (0 min) and at 15, 30,
60, and 120 min after injection.
BLOOD PARAMETERS, TISSUE PREPARATION, AND MORPHOMETRIC
ANALYSIS OF VASCULAR LESION
Total cholesterol concentrations were measured with standard
enzymatic assays (Infinity, Cholesterol and Triglyceride kit;
Thermo Fisher Scientific, Waltham, MA, USA). Samples were
analyzed individually except for lipoprotein separation in which
pooled samples (0.25 ml) from 10 animals per group were sub-
jected to fast-performance liquid chromatography (FPLC) gel
filtration on two Superose six columns connected in series.
Atherosclerosis was quantified using en-face analysis of the aortic
intima of the arch and thorax, as described previously (Daugherty
and Whitman, 2003).
STATISTICAL ANALYSIS
All statistical analysis was performed with Prism 5.0 (GraphPad
Software,La Jolla,CA,USA). Statistical differences between groups
were determined by Student’s t -test. A P value less than 0.05 was
considered significant.
RESULTS
ENDOGENOUS GHRELIN SIGNALING HAD NO EFFECT ON
HYPERCHOLESTEROLEMIA IN MICE
Studies described in this report were conducted in LDLr-deficient
mice, one of the most utilized genetic mouse models for the
study of atherosclerosis. Lack of LDLr in mice (LDLr−/−) induces
a profound increase in circulating cholesterol concentrations
when mice are fed a saturated fat diet. LDLr−/− mice were
crossed with GHSr−/− mice, creating double knockout mice
(GHSr/LDLr−/−) that allowed us to evaluate the role of ghre-
lin signaling in lipoprotein metabolism and the progression of
atherosclerosis. Male, age-matched mice lacking LDLr displayed
profound hypercholesterolemia (1505 ± 82.6 mg/dl). Deletion of
both LDLr and GHSr resulted in similar levels of plasma cho-
lesterol (1478± 175.3 mg/dl) as those observed in LDLr−/−mice
(Figure 1A). FPLC analyses of plasma from these mice elucidated
similar characteristics in terms of cholesterol particle distribu-
tion. Specifically, mice of both genotypes displayed considerable
peaks in very low-density lipoprotein (VLDL) and LDL fractions
(Figure 1B). Furthermore, deletion of the ghrelin receptor was
unable to rescue the depressed concentrations of HDL-cholesterol
observed with deletion of the LDL receptor (Figure 1B).
ENDOGENOUS GHRELIN SIGNALING DID NOT AFFECT
ATHEROSCLEROSIS
We next evaluated the protective role of ghrelin signaling via GHSr
in the context of atherosclerotic progression. LDLr−/− mice main-
tainedon a saturated fat diet displayed considerable atherosclerosis
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in the aortic arch, with lesion areas of 12.01± 0.99 mm2
(Figure 2A) that covered 55.77± 3.45% of the assayed area
(Figure 2B). As with LDLr−/− mice, GHSr/LDLr−/− mice also
showed considerable atherosclerosis of the aortic arch. Mice
with the double knockout mutation displayed lesion areas of
13.46± 1.31 mm2 (Figure 2A) and covered 54.86± 3.75% of the
intimal area (Figure 2B). In addition to the aortic arch, we also
analyzed atherosclerotic development along the thoracic aorta.
Like lesions present in the arch, those of the thoracic aorta were of
similar size (Figures 3A,B) in both LDLr−/− and GHSr/LDLr−/−
FIGURE 1 |Total plasma cholesterol concentrations (A) and analysis of
plasma lipoproteins (B) in male mice fasted overnight. Pooled plasma
(0.25ml) from 10 GSHr/LDLr−/− (open circles) and 10 LDLr−/− (closed
circles) mice maintained on atherogenic diet was applied to two FPLC
Superose columns, and 0.5-ml fractions were collected for cholesterol
determinations. According to calibration with standard lipoproteins, the
peak fractions 5–9 represent VLDL, fractions 10–20 are mainly IDL/LDL
particles, and fractions 20–26 contain mainly HDL.
FIGURE 2 | Atherosclerosis was measured on aortic arches from male
GHSr+/+LDLr−/− (open circles, n =10) and GHSr−/−LDLr−/− (closed
circles, n =10) mice.The extent of intimal surface covered by grossly
discernible lesions was determined from en-face preparations of the aortic
intima in the arch region. Data were expressed as lesion area of the arch
(A) and as percent area covered by atherosclerosis (B).
mice (11.29± 2.59 vs. 6.74± 1.46 mm2) and covered similar
portions of the assayed area (30.62± 5.75 vs. 20.15± 4.13%).
GHRELIN REGULATION OF BODY COMPOSITION AND GLUCOSE
HOMEOSTASIS IN LDLr-DEFICIENT MICE
Low-density lipoprotein receptor-null and GHSr/LDLr−/− mice
had similar body weight (Figure 4A), lean, and fat mass
(Figures 4B,C), suggesting that lack of ghrelin signaling through
GHSr does not alter body composition in LDLr−/− mice. Similar
to our earlier findings (Pfluger et al., 2008), and consistent
with our body weight and fat mass results, lack of GHSr-
mediated ghrelin signaling had no effect on glucose tolerance,
resulting in similar glucose excursions in both LDLr−/− and
GHSr/LDLr−/− mice (AUC= 73371± 1098 and 74706± 1443,
respectively; Figures 4D,E).
DISCUSSION
The connection between obesity and cardiovascular disease has
been the focus of intense research. Recent findings have brought
forth several mutual pathways that may be dysregulated in both
disease states. Among these regulators, the role of ghrelin in
atherosclerosis has yet to be fully elucidated. Specifically, it has
been argued that ghrelin is protective against the development of
atherosclerosis.
We therefore carefully evaluated the role of GHSr-mediated
ghrelin signaling in a common mouse model of atherosclerosis.
As such, this study is the first to our knowledge that assesses the
mechanistic role of ghrelin in atherosclerosis in an in vivo setting.
While we were able to elicit a profound atherosclerotic state in
LDLr−/− mice in the presence of an atherogenic diet, we failed
to detect an effect on the degree of atherosclerosis in the ghrelin
receptor loss-of-function mice.
A potential caveat of this study is the choice of the athero-
sclerotic mouse model, the LDLr−/− mouse. These mice develop
extreme hypercholesterolemia that may not be amendable by a
single geneticmanipulation.Accordingly, this is not the first exam-
ple of an observation made in humans that could not be directly
translated to the LDLr−/− model of atherosclerosis (Nawrocki
et al., 2010). In addition, our finding that fasting glucose levels
and glucose tolerance are similar between LDLr−/− mice with or
without GHSr also shows that the previously reported enhance-
ment of insulin sensitivity in GHSr−/− mice (Longo et al., 2008)
FIGURE 3 | Atherosclerosis was measured on the thoracic aorta from
male GHSr+/+LDLr−/− (open circles, n=7) and GHSr−/−LDLr−/− (closed
circles, n =7) mice.The extent of intimal surface covered by grossly
discernible lesions was determined from en-face preparations of the aortic
intima in the thoracic region. Data were expressed as lesion area of the
thoracic aorta (A) and as percent area covered by atherosclerosis (B).
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FIGURE 4 | Body weight (A), fat mass (B), and glucose tolerance
(C) were assessed after 13months of western-style diet in male
mice. A glucose tolerance test (GTT) was conducted using an i.p. dose
of 1.5 g of glucose per kg of body weight in GHSr+/+LDLr-/- (open
circles, n =12) and GHSr-/-LDLr-/- (closed circles, n =10) mice fasted
for 6 h. (D,E) are data from the ipGTT. (D) displays ipGTT data as
collected at each time point, and (E) displays this data as the
integrated, area under the curve.
did not translate into our mouse model of atherosclerosis and thus
may have interfered with an otherwise potential beneficial indi-
rect effect of GHSr on the atherogenetic process. Furthermore, at
the time of lesion analysis, these mice had been maintained on
the high-fat, high-cholesterol “Western” diet for 13 months. This
extended exposure to the atherogenic diet may have masked any
temporary effects exerted through the ghrelin receptor.
On the surface, these findings seem difficult to reconcile
with the considerable number of descriptive, pharmacological,
or in vitro reports suggesting a role for ghrelin signaling in the
pathogenesis of atherosclerosis. However, the ghrelin system plays
numerous and pleiotropic roles in the control of cardiovascular
risk factors associated with energy, glucose and lipid metabolism.
It is important to note that in this experimental model ghrelin
signaling, or lack thereof, is restricted to GHSr-mediated events.
As such this model focuses on the physiological role of acylated
ghrelin and its direct signaling through GHSr in the progression
of atherosclerosis. However, this paradigm does not exclude a
potential effect that is regulated by desacyl-ghrelin, obestatin, or
other ghrelin prepropetide variants that are mediated by receptors
other than GHSr (see review by Muccioli et al., 2007). In addi-
tion, ghrelin has been reported to directly modulate several targets
and processes with direct relevance for atherosclerosis (see review
by Zhang et al., 2010). It therefore appears possible that direct
and indirect impacts of ghrelin action may have mutually oppo-
site effects on the development of atherosclerosis, at least in this
double-loss-of-function mouse model.
Our findings may indicate potential limitations of the LDL
receptor mouse model in reproducing associations that have been
established inhumans.Unlike humans,mice are resistant to plaque
rupture and myocardial infarction. In our studies, genetic manip-
ulation of ghrelin signaling through GHSr, in a traditional rodent
model of atherosclerosis did not correlate with atherosclerosis.
These data suggest that ghrelin, or at least ghrelin signaling
mediated via the ghrelin receptor, is not involved in advanced
plaque progression. Alternatively, ghrelin-induced effects on the
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pathogenesis of atherosclerosis in one or the other direction
may be mediated by an alternative ghrelin receptor, which has
repeatedly been postulated to exist (Cassoni et al., 2004; Granata
et al., 2007), but remains to be identified. Until then, the present
data suggest that ghrelin-based therapeutics may not provide the
previously assumed considerable potential for the prevention or
treatment of atherosclerosis.
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